Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.53 |
| ▸ | GRM5 | P41594 | 11/20 | 0.53 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.48 |
| ▸ | WNT3A | P56704 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21245864 | 1.00 | GRM1 (0.53) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL18202599 | 0.86 | GRM1 (0.53) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL21460207 | 0.86 | GRM1 (0.53) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL29498320 | 0.86 | GRM1 (0.53) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL13096687 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL30198712 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL31701242 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL64945 | 0.85 | GRM1 (0.55) | GRM1GRM5PDK4ATRCYP11B2 | |
| SCHEMBL24891678 | 0.84 | GRM1 (0.52) | GRM1GRM5PDK4CYP11B2WNT3A | |
| SCHEMBL13521354 | 0.83 | PDK4 (0.51) | GRM1GRM5PDK4ATRCYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | GRM1 2912/4885GRM5 3400/4885PDK4 153/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | GRM1 4339/4885GRM5 4279/4885PDK4 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.